CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Supply Chain

Future-Proofing a Volatile Supply Chain Through Modular Biomanufacturing

Rasmus Pedersen, Ph.D.; John Stewart; Peter Skals

Fujifilm Biotechnologies

HTS

The High-Throughput Screening Transformation in Modern Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Developability

Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments

Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.

Coriolis Pharma

Developability

Streamlining the Path to Approval with Developability and Pre-Formulation Platforms

Andrea Hawe

Coriolis Pharma

CRDO

Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development

Silvia Steyrer-Gruber

Coriolis Pharma

mRNA Manufacturing

Navigating mRNA Manufacturing with Flexibility and Innovation

Michael van der Horst, Ph.D.

Wacker Chemie AG

CDMO

Advanced Technologies Unlocking the Future of Drug Manufacturing

Jon Brice

Asymchem

Cleanrooms

Design–Build Cleanroom Projects: A Proven Risk Mitigating Methodology

Matt Dean; Mitchell Gonzales

AES Clean Technology Inc.

New CDMO Facility

Leveraging a State-of-the-Art CDMO Facility to Advance Healthcare

Grifols

Overcoming the Challenges of an Ever-changing Biopharma Landscape

Integrity

Quality by Design

A Concerted QbD Approach to Development and Manufacturing of Nucleic Acid Therapies

Grant Henderson, Ph.D.; Lynda Menard, Ph.D.

Vernal Biosciences

Viral Vectors

Risk-Based Optimization of Viral Vector Processes Adds Real Value

Elie Hanania, Ph.D.; Tatiana Mello, M.S.

Avid Bioservices

Pharma 4.0

Applying an Advanced Pharma 4.0 Perspective to Design the Facility of the Future

Steve Attig; Yuk Chun Chiu, M.S.E.; Yvonne Duckworth; Patricia Robbins; Dawn Wofford

CRB USA

CAPA Management

CAPA Management is Worth Doing, and Worth Doing Well

Helen Lowe

Nitrosamine

Supporting Drug Manufacturers with Emprove® Nitrosamine Declarations

Ulrich Reichert, M.D.R.A.

MilliporeSigma

Roundtable

Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?

Pharma's Almanac

Equipment

Fit Biopharmaceutical Facilities: A Predictive Maintenance Approach

CRB USA